Open AccessEffects of KB-5492, 1-(3,4,5-Trimethoxybenzyl)-4-((4-Methoxyphenyl)oxycarbonylmethyl)piperazine Monofumarate Monohydrate, on Gastric Lesions and Gastric Secretion in Rats
Author(s) -
Koichi Shimohara,
Hiromichi Niida,
Susumu Okabe
Publication year - 1990
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.53.275
Subject(s) - ed50 , gastric acid , gastric secretion , aspirin , secretion , histamine , chemistry , pharmacology , prednisolone , piperazine , drug , medicine , endocrinology , biochemistry , in vitro
Effects of a newly synthesized compound, KB-5492, on gastric lesions and gastric secretion were studied in rats. Oral KB-5492 inhibited the lesions induced by HCl.ethanol, HCl.aspirin, water-immersion stress, indomethacin, histamine and prednisolone at 30-300 mg/kg. The ED50 values varied from about 35 to 98 mg/kg. KB-5492 had no effect on gastric acid secretion even at 300 mg/kg. KB-5492 appeared to have a much more potent protective effect than a known anti-ulcer drug, sofalcone, against acute gastric lesions.